TYPE 2 DIABETES MELLITUS PREVENTION – PRESCRIPTIONS OFF-LABEL

L. J. O. Andrade, Paulo Roberto Santana de Melo, M. Margotto, A. Bittencourt
{"title":"TYPE 2 DIABETES MELLITUS PREVENTION – PRESCRIPTIONS OFF-LABEL","authors":"L. J. O. Andrade, Paulo Roberto Santana de Melo, M. Margotto, A. Bittencourt","doi":"10.17267/2317-3386BJMHH.V2I1.304","DOIUrl":null,"url":null,"abstract":"The prescribing a drug without the indications for which the drug was originally approved by regulators is internationally known as prescribing “off-label”. Objective: To describe the off-label prescriptions in type 2 diabetes (DM2) prevention, reported international scientific literature, through an integrative bibliographical review. Method: An integrative review was made by searching the Medline international database for review of manuscripts. Selection of these databases was based on the wide range of journals covered by each of them and our goal was to provide an overview of the scientific production devoted to the topic over the timeframe under analysis. The following inclusion criteria were considered during the review: articles published between January 1985 and June 2013; use of the keywords “off-label use” OR “off-label” OR “off-label prescribing” OR “diabetes prevention” OR “prevention” MeSH “diabetes mellitus” entered into the search form, and availability of an abstract in English. Results: A total 852 scientific productions were identified, and 30 studies were selected by contain information about the off-label prescriptions in DM2. Conclusion: The practice of off-label prescribing itself has notable benefits. In some situations, an off-label prescription is the only treatment available to a patient, either because a more targeted drug is does not exist, or because other methods of treatment are ineffective or unavailable due to patient intolerance. In these situations, off-label uses of drugs provide the only chance of restored health.","PeriodicalId":280405,"journal":{"name":"Brazilian Journal of Medicine and Human Health","volume":"71 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2014-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brazilian Journal of Medicine and Human Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17267/2317-3386BJMHH.V2I1.304","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The prescribing a drug without the indications for which the drug was originally approved by regulators is internationally known as prescribing “off-label”. Objective: To describe the off-label prescriptions in type 2 diabetes (DM2) prevention, reported international scientific literature, through an integrative bibliographical review. Method: An integrative review was made by searching the Medline international database for review of manuscripts. Selection of these databases was based on the wide range of journals covered by each of them and our goal was to provide an overview of the scientific production devoted to the topic over the timeframe under analysis. The following inclusion criteria were considered during the review: articles published between January 1985 and June 2013; use of the keywords “off-label use” OR “off-label” OR “off-label prescribing” OR “diabetes prevention” OR “prevention” MeSH “diabetes mellitus” entered into the search form, and availability of an abstract in English. Results: A total 852 scientific productions were identified, and 30 studies were selected by contain information about the off-label prescriptions in DM2. Conclusion: The practice of off-label prescribing itself has notable benefits. In some situations, an off-label prescription is the only treatment available to a patient, either because a more targeted drug is does not exist, or because other methods of treatment are ineffective or unavailable due to patient intolerance. In these situations, off-label uses of drugs provide the only chance of restored health.
预防2型糖尿病——处方说明书外
在没有获得监管机构最初批准的适应症的情况下开药,在国际上被称为“标签外”开药。目的:通过综合文献综述,描述国际科学文献报道的2型糖尿病(DM2)预防的超说明书处方。方法:通过检索Medline国际数据库进行文献综述。这些数据库的选择是基于每个数据库所涵盖的广泛期刊,我们的目标是提供在分析的时间框架内致力于该主题的科学生产的概述。在审查过程中考虑了以下纳入标准:1985年1月至2013年6月期间发表的文章;使用关键词“超说明书使用”或“超说明书使用”或“超说明书处方”或“糖尿病预防”或“预防”MeSH“糖尿病”输入搜索表格,并可获得英文摘要。结果:共鉴定出852篇科学论文,通过包含DM2超说明书处方信息筛选出30篇研究。结论:超说明书处方的实践本身具有显著的效益。在某些情况下,说明书外处方是患者唯一可用的治疗方法,要么是因为不存在更有针对性的药物,要么是因为其他治疗方法无效或由于患者不耐受而无法获得。在这些情况下,未经核准使用药物是恢复健康的唯一机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信